Inhibition of Focal Adhesion Kinase by PF-562,271 Inhibits the Growth and Metastasis of Pancreatic Cancer Concomitant with Altering the Tumor Microenvironment

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2011-09-08

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1535-7163.MCT-11-0261PMID 21903606PMCID PMC3213273
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

  2023cited by this paper
• CA : A Cancer Journal for Clinicians

  2011cited by this paper
• Cancer Statistics, 2009

  2009cited by this paper
• Differential requirement for focal adhesion kinase signaling in cancer progression in the transgenic adenocarcinoma of mouse prostate model

  2009cited by this paper
• Dual focal adhesion kinase/Pyk2 inhibitor has positive effects on bone tumors

  2008cited by this paper
• Cancer-associated stromal fibroblasts promote pancreatic tumor progression.

  2008cited by this paper
• Focal adhesion kinase as a regulator of cell tension in the progression of cancer.

  2008cited by this paper
• Role of myofibroblasts in innate chemoresistance of pancreatic carcinoma—Epigenetic downregulation of caspases

  2008cited by this paper
• Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.

  2008influential reference
• Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

  2007cited by this paper
• Regulation of lamellipodial persistence, adhesion turnover, and motility in macrophages by focal adhesion kinase

  2007cited by this paper
• Tumor-stroma interactions in pancreatic ductal adenocarcinoma

  2007cited by this paper
• Cellular Characterization of a Novel Focal Adhesion Kinase Inhibitor*

  2007cited by this paper
• Focal adhesion kinase as a marker of invasive potential in differentiated human thyroid cancer

  2006cited by this paper
• Clinical Significance of Focal Adhesion Kinase in Resectable Pancreatic Cancer

  2006cited by this paper
• Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.

  2005cited by this paper
• Focal adhesion kinase: in command and control of cell motility

  2005cited by this paper
• Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

  2005cited by this paper
• Focal adhesion kinase is required for the spatial organization of the leading edge in migrating cells

  2005cited by this paper
• Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC)

  2005cited by this paper
• Role of Expression of Focal Adhesion Kinase in Progression of Hepatocellular Carcinoma

  2004cited by this paper
• Focal adhesion kinase gene silencing promotes anoikis and suppresses metastasis of human pancreatic adenocarcinoma cells.

  2004cited by this paper
• FAK overexpression is correlated with tumour invasiveness and lymph node metastasis in oesophageal squamous cell carcinoma

  2003cited by this paper
• Focal adhesion kinase: the first ten years

  2003cited by this paper
• Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

  2002cited by this paper
• Dual Inhibition of Focal Adhesion Kinase and Epidermal Growth Factor Receptor Pathways Cooperatively Induces Death Receptor-mediated Apoptosis in Human Breast Cancer Cells*

  2002cited by this paper
• Biochemical signals and biological responses elicited by the focal adhesion kinase.

  2001cited by this paper
• Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes.

  2000cited by this paper
• Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells

  1999cited by this paper
• Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma

  1999cited by this paper
• In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice.

  1999cited by this paper
• Signaling through focal adhesion kinase.

  1999influential reference
• Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

  1997cited by this paper
• pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions.

  1992cited by this paper
• Cancer statistics

  1989cited by this paper

• Research progress on the influence of tumor microenvironment on immunotherapy for pancreatic ductal adenocarcinoma

  2026cites this paper
• Spatial regulation of mitochondrial membrane potential by 𝛂5ꞵ1 integrin engagement in collective cell migration.

  2025cites this paper
• Fibrotic Fortresses and Therapeutic Frontiers: Pancreatic Stellate Cells and the Extracellular Matrix in Pancreatic Cancer

  2025cites this paper
• PRMT5 Identified as a Viable Target for Combination Therapy in Preclinical Models of Pancreatic Cancer

  2025cites this paper
• Development of a high-throughput TR-FRET assay to identify inhibitors of the FAK-paxillin protein-protein interaction.

  2025cites this paper
• Therapeutic potential of isochlorogenic acid A from Taraxacum officinale in improving immune response and enhancing the efficacy of PD-1/PD-L1 blockade in triple-negative breast cancer

  2025cites this paper
• Research progress of PYK2 in digestive system diseases

  2025influential citation
• Immune-Based Strategies for Pancreatic Cancer in the Adjuvant Setting

  2025cites this paper
• Targeting FAK to Potentiate Immune Checkpoint Therapy in Solid Tumors

  2025cites this paper
• Sensitivity of Pancreatic Cancer Cell Lines to Clinically Approved FAK Inhibitors: Enhanced Cytotoxicity Through Combination with Oncolytic Coxsackievirus B3

  2025cites this paper
• Biomimetic Tumour Model Systems for Pancreatic Ductal Adenocarcinoma in Relation to Photodynamic Therapy

  2025cites this paper
• Targeting Focal Adhesion Kinase in Lung Diseases: Current Progress and Future Directions

  2025cites this paper
• Focal adhesion kinase inhibition enhances response to checkpoint immunotherapy in hepatocellular carcinoma

  2025cites this paper
• FBXO32 Stimulates Protein Synthesis to Drive Pancreatic Cancer Progression and Metastasis.

  2024cites this paper
• A proteomics approach to isolating neuropilin-dependent α5 integrin trafficking pathways: neuropilin 1 and 2 co-traffic α5 integrin through endosomal p120RasGAP to promote polarised fibronectin fibrillogenesis in endothelial cells

  2024cites this paper
• Targeting focal adhesion kinase boosts immune response in KRAS/LKB1 co-mutated lung adenocarcinoma via remodeling the tumor microenvironment

  2024cites this paper
• Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapy

  2024cites this paper
• A histone methylation-MAPK signaling axis drives durable epithelial-mesenchymal transition in hypoxic pancreatic cancer.

  2024cites this paper
• Comprehensive pan-cancer analysis of 33 human cancers reveals immunotherapeutic value of focal adhesion tyrosine kinase

  2024cites this paper
• Inhibition of phospholipase D1 reduces pancreatic carcinogenesis in mice partly through a FAK-dependent mechanism.

  2024cites this paper
• Challenges and Opportunities in Targeting the Complex Pancreatic Tumor Microenvironment

  2024cites this paper
• FAK suppresses antigen processing and presentation to promote immune evasion in pancreatic cancer

  2023cites this paper
• Engine shutdown: migrastatic strategies and prevention of metastases.

  2023cites this paper
• High frequency of alternative splicing variants of the oncogene Focal Adhesion Kinase in neuroendocrine tumors of the pancreas and breast

  2023cites this paper
• Together, Neuropilin 1 and Neuropilin 2 direct α5 integrin trafficking through GTPase-activating-protein p120RasGAP in endothelial cells to promote fibronectin fibrillogenesis

  2023cites this paper
• Supervised learning on impedance cytometry data for label-free biophysical distinction of pancreatic cancer cells versus their associated fibroblasts under gemcitabine treatment.

  2023cites this paper
• Focal adhesion kinase: from biological functions to therapeutic strategies

  2023cites this paper
• Interrogating the CD27:CD70 axis in αCD40-dependent control of pancreatic adenocarcinoma

  2023cites this paper
• A histone methylation-MAPK signaling axis drives durable epithelial-mesenchymal transition in hypoxic pancreas cancer

  2023cites this paper
• Pyk2/FAK Signaling Is Upregulated in Recurrent Glioblastoma Tumors in a C57BL/6/GL261 Glioma Implantation Model

  2023cites this paper
• Macrophages as a Therapeutic Target in Metastatic Prostate Cancer: A Way to Overcome Immunotherapy Resistance?

  2022cites this paper
• Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment

  2022cites this paper
• Autophagy Modulation and Cancer Combination Therapy: A Smart Approach in Cancer Therapy.

  2022cites this paper
• FAK in Cancer: From Mechanisms to Therapeutic Strategies

  2022cites this paper
• Orchestration of mesenchymal plasticity and immune evasiveness via rewiring of the metabolic program in pancreatic ductal adenocarcinoma

  2022cites this paper
• Network-based approach for targeting human kinases commonly associated with amyotrophic lateral sclerosis and cancer

  2022cites this paper
• Defactinib, pembrolizumab, and gemcitabine in patients with advanced treatment refractory pancreatic cancer: A phase I, dose escalation, and expansion study.

  2022cites this paper
• Integrin signaling is critical for myeloid-mediated support of T-cell acute lymphoblastic leukemia

  2022cites this paper
• Suppression of Endothelial Cell FAK Expression Reduces Pancreatic Ductal Adenocarcinoma Metastasis after Gemcitabine Treatment

  2022cites this paper
• Automated biophysical classification of apoptotic pancreatic cancer cell subpopulations by using machine learning approaches with impedance cytometry

  2022cites this paper
• Tumor-associated macrophage (TAM)-derived CCL22 induces FAK addiction in esophageal squamous cell carcinoma (ESCC)

  2022cites this paper
• Focal adhesion kinase priming in pancreatic cancer, altering biomechanics to improve chemotherapy

  2022cites this paper
• Enhancing therapeutic anti-cancer responses by combining immune checkpoint and tyrosine kinase inhibition

  2022cites this paper
• Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma

  2022influential citation
• Enhancing CRISPR/Cas gene editing through modulating cellular mechanical properties for cancer therapy

  2022cites this paper
• Recent progress on FAK inhibitors with dual targeting capabilities for cancer treatment.

  2022cites this paper
• Stromal reprogramming by FAK inhibition overcomes radiation resistance to allow for immune priming and response to checkpoint blockade.

  2022cites this paper
• Immunotherapy: Reshape the Tumor Immune Microenvironment

  2022cites this paper
• Opposite roles of Kindlin orthologs in cell survival and proliferation

  2022cites this paper
• Immunotherapy for pancreatic cancer: chasing the light at the end of the tunnel

  2021cites this paper
• Targeting FAK in anticancer combination therapies

  2021cites this paper
• SY-707, an ALK/FAK/IGF1R inhibitor, suppresses growth and metastasis of breast cancer cells

  2021influential citation
• Apoptotic Bodies in the Pancreatic Tumor Cell Culture Media Enable Label‐Free Drug Sensitivity Assessment by Impedance Cytometry

  2021cites this paper
• Advances in Pancreatic Ductal Adenocarcinoma Treatment

  2021cites this paper
• The Adhesome Network: Key Components Shaping the Tumour Stroma

  2021influential citation
• Focal Adhesion Kinase Fine Tunes Multifaced Signals toward Breast Cancer Progression

  2021cites this paper
• Next-generation immunotherapy for pancreatic ductal adenocarcinoma: navigating pathways of immune resistance

  2021cites this paper
• High expression of PYK2 is associated with poor prognosis and cancer progression in early-stage cervical carcinoma

  2021cites this paper
• Uncovering key targets of success for immunotherapy in pancreatic cancer

  2021cites this paper
• Stromal architecture directs early dissemination in pancreatic ductal adenocarcinoma

  2021cites this paper
• Extracellular Matrices and Cancer-Associated Fibroblasts: Targets for Cancer Diagnosis and Therapy?

  2021cites this paper
• Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy

  2021cites this paper
• Validation of a multicellular tumor microenvironment system for modeling patient tumor biology and drug response

  2021cites this paper
• Metabolic radiolabeling and in vivo PET imaging of cytotoxic T lymphocytes to guide combination adoptive cell transfer cancer therapy

  2021cites this paper
• The Role of Noncoding RNAs in the Regulation of Anoikis and Anchorage-Independent Growth in Cancer

  2021cites this paper
• Identification of Thieno[3,2-d]pyrimidine Derivatives as Dual Inhibitors of Focal Adhesion Kinase and FMS-like Tyrosine Kinase 3.

  2021cites this paper
• Focal adhesion kinase inhibitors in the treatment of solid tumors: preclinical and clinical evidence.

  2021cites this paper
• Cancer-Associated Fibroblast (CAF) Heterogeneity and Targeting Therapy of CAFs in Pancreatic Cancer

  2021cites this paper
• Distinct roles for the RNA-binding protein Staufen1 in prostate cancer

  2021cites this paper
• Focal adhesion kinase inhibitors, a heavy punch to cancer

  2021influential citation
• Structure-Based Virtual Screening, Synthesis and Biological Evaluation of Potential FAK-FAT Domain Inhibitors for Treatment of Metastatic Cancer

  2020cites this paper
• Recognition of LD motifs by the focal adhesion targeting domains of focal adhesion kinase and proline‐rich tyrosine kinase 2‐beta: Insights from molecular dynamics simulations

  2020cites this paper
• Targeting the Extra-Cellular Matrix—Tumor Cell Crosstalk for Anti-Cancer Therapy: Emerging Alternatives to Integrin Inhibitors

  2020cites this paper
• Molecular mediators of peritoneal metastasis in pancreatic cancer

  2020cites this paper
• Phosphorylation of pericyte FAK-Y861 affects tumour cell apoptosis and tumour blood vessel regression

  2020cites this paper
• Regulation and modulation of antitumor immunity in pancreatic cancer

  2020cites this paper
• Pancreatic cancer stroma: an update on therapeutic targeting strategies

  2020cites this paper
• The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities

  2020cites this paper
• Rab18 regulates focal adhesion dynamics by interacting with kinectin-1 at the endoplasmic reticulum

  2020cites this paper
• FAK Family Kinases in Vascular Diseases

  2020cites this paper
• FAK activity in cancer‐associated fibroblasts is a prognostic marker and a druggable key metastatic player in pancreatic cancer

  2020cites this paper
• FAK promotes stromal PD-L2 expression associated with poor survival in pancreatic cancer

  2020cites this paper
• Determinants of Resistance to Checkpoint Inhibitors

  2020cites this paper
• Involvement of the FAK Network in Pathologies Related to Altered Mechanotransduction

  2020cites this paper
• New Potential Therapeutic Strategy of Pancreatic Cancer via Targeting the Tumor Microenvironment

  2020cites this paper
• FAK-targeted and combination therapies for the treatment of cancer: an overview of phase I and II clinical trials

  2020cites this paper
• Cancer-associated fibroblasts in desmoplastic tumors: emerging role of integrins.

  2020cites this paper
• A Fyn biosensor reveals pulsatile, spatially localized kinase activity and signaling crosstalk in live mammalian cells

  2020cites this paper
• Focal adhesion kinase—An emerging viable target in cancer and development of focal adhesion kinase inhibitors

  2020cites this paper
• Epithelial-mesenchymal transition: a hallmark in pancreatic cancer stem cell migration, metastasis formation, and drug resistance

  2020cites this paper
• Electrophysiology-based stratification of pancreatic tumorigenicity by label-free single-cell impedance cytometry.

  2020cites this paper
• FAK Promotes Early Osteoprogenitor Cell Proliferation by Enhancing mTORC1 Signaling

  2020influential citation
• Immunotherapy in Pancreatic Cancer

  2020cites this paper
• T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity

  2020cites this paper
• Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages

  2019cites this paper
• Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy

  2019cites this paper
• Heart failure as interstitial cancer: emergence of a malignant fibroblast phenotype

  2019cites this paper
• Therapeutic Implication of SOCS1 Modulation in the Treatment of Autoimmunity and Cancer

  2019cites this paper
• Immune Checkpoint Inhibitors in Gastrointestinal Malignancies

  2019cites this paper
• Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1+ triple negative breast cancer cells

  2019cites this paper